Among 80 patients who underwent out-of-pocket multigene panel testing, 17 (21.2%) carried pathogenic variants (PV) in cancer susceptibility genes, including 12 (15%) patients with BRCA1/BRCA2 PV, two (2.5%) with TP53 PV, one with p.R337H and one with non-R337H TP53 PV (p.W146X), along with 3 (3.7%) in genes not associated with HBC (Table S3 in the Supplementary Materials). This evidence concerns the gene BRCA2 and cancer.